Telaglenastat was effectively tolerated at day-to-day doses larger than 1 g with a few evidence of single-agent activity in relapsed/refractory leukemia sufferers (66). Even so, generally, The only-agent exercise was modest, and subsequent initiatives have centered on blend therapies. By way of example, a mix review with panitumumab and irinotecan https://leonardow530glq3.blog-a-story.com/profile